U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399782) titled 'Botulinum Toxin in the Palatopharyngeal Muscle for the Treatment of Obstructive Sleep Apnea' on Aug. 02, 2025.
Brief Summary: Obstructive Sleep Apnea (OSA) is a sleep-related breathing disorder characterized by recurrent collapse of the upper airway during sleep, in which the palatopharyngeal muscle plays a key role in pathophysiology. Although continuous positive airway pressure (CPAP) remains the standard treatment, adherence is often suboptimal. Botulinum toxin type A (BoNT-A), a peripheral neuromodulator, has been proposed as a potential therapeutic alternative by inducing chemodenervation and muscle volume reduction, thereby po...